Treatment with risankizumab following inadequate response to secukinumab or ixekizumab was associated with improved disease severity, quality of life, and symptoms among patients with plaque psoriasis ...

CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments. "We are very optimistic about the prospects of our ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.

Q: I was just diagnosed with Type 2 diabetes. I feel like the doctor is expecting me to do his job! He loaded me down with a ...

Emissions Reduction Alberta (ERA) : The Government of Alberta and Natural Resources Canada just committed a combined $50M for ERA's new Strategic Energy Management for Industry (SEMI) program. They ...

ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net ...

Werewolf Therapeutics, Inc. (the "Company” or "Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data ...

The following is a summary of “Prognostic role of cardiac and inflammatory biomarkers in extubation failure in patients with COVID-19 acute respiratory distress syndrome,” published in the January ...

This study aimed to investigate the association between the interleukin-1 beta (IL-1β) gene polymorphism (rs2853550) and the risk of rheumatoid arthritis (RA) in a sample of the Iraqi population. The ...

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for ...